NCT03976336View on ClinicalTrials.gov

Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Metabolic Syndrome
Interventions
DIETARY_SUPPLEMENT

Berberine

500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total

OTHER

Identical Placebo

500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT03976336 - Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study | Biotech Hunter | Biotech Hunter